Longboard Pharmaceuticals Inc (LBPH): Market Capitalization-to-Revenue Ratio
Longboard Pharmaceuticals is shaping the treatment landscape for rare brain pathologies by establishing standards of care for epilepsy. The company is implementing software robots for clinical analysis and automating molecule screening. Drug development is based on a virtual model utilizing external manufacturing facilities in the US. The divergence of the P/S ratio from its historical average demonstrates valuation dynamics, where the metric serves as the target level.
Analytical breakdowns for Longboard Pharma (LBPH)
- stock value and consensus price forecast:
- stock exchange capitalization data:
- book capitalization indicators:
- debt obligations and liquidity statistics:
Aggregate Debt to Equity Longboard Pharmaceuticals|LBPH - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Longboard|LBPH - Company Aggregate Debts|Debts to Book Capitalization Longboard Pharma|LBPH - Company Long-Term Debt|Company Short-Term Loans and Borrowings Longboard Pharmaceuticals|Quick Liquidity Indicator longboardpharma.com
- net income and valuation multiples indicators:
LBPH - Net Profit|Projected Future Earnings Longboard Pharmaceuticals|LBPH - P/E Multiple|Projected Price to Earnings Longboard Pharmaceuticals Inc|LBPH - PEG Multiple|Company Value to EBITDA Longboard Pharma|LBPH - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Longboard Pharmaceuticals|LBPH - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months longboardpharma.com|LBPH - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Longboard Pharmaceuticals
- sales revenue and business income indicators:
General company analysis:LBPH longboardpharma.com
The P/S ratio relates the market value of Longboard Pharmaceuticals (LBPH) to its annual revenue, revealing the gap between stock quotes and actual cash flows. Analyzing the price-to-sales ratio allows for an assessment of the biotech's capitalization fairness, where the potential of bexicaserin in epilepsy therapy and the prospect of acquisition by pharma behemoths may justify a high premium over current sales.
Competitors of Longboard Pharmaceuticals
P/S Multiple biogen.com (BIIB)|Price-to-Revenue Ratio Neurocrine Biosciences, Inc. NBIX|Market Capitalization-to-Revenue Ratio RGC|Axsome Therapeutics Inc - P/S Multiple|ACAD (ACADIA Corp) - Market Cap to Revenue Ratio|XENE (Xenon Pharmaceuticals) - Market Cap to Revenue|vikingtherapeutics.com - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Supernus|Catalyst Pharma - Price-to-Sales Ratio|P/S Multiple DNLI|HRMY (Harmony Corp) - Market Capitalization-to-Revenue Ratio|P/S Multiple BHVN (Biohaven Ltd.)|P/S Multiple amylyx.com AMLX|TRVI - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio PRAX (Praxis Precision Medicines Inc)|Anavex Corp (AVXL) - Price-to-Revenue Ratio|Market Cap to Revenue CeriBell EEG|PRTA (Prothena Biosciences) - P/S Multiple|P/S Multiple Alector Therapeutics|P/S Multiple ANNX|Market Cap to Revenue omeros.com OMER|P/S Multiple NGNE (Neurogene Corp)|AC Immune Inc (ACIU) - Price to Sales|VYGR: Market Cap to Revenue|NMRA - P/S Multiple|SCLX (Scilex) - Market Cap to Revenue|TVGN: Market Cap to Sales Volume|ACOG (Alpha Cognition Inc) - P/S Multiple|Cognition Therapeutics Inc. (CGTX) - Price-to-Revenue Coefficient|P/S Multiple IKT|Market Cap to Revenue cassavasciences.com SAVA|P/S Multiple ASRT (Assertio)|P/S Multiple Coya Therapeutics Inc COYA|VTGN - Price-to-Revenue Ratio|OVID: Price-to-Revenue Ratio|Acumen Pharmaceuticals (ABOS) - Price-to-Revenue Ratio|CRVO - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Alterity Therapeutics Ltd.|Price-to-Revenue Ratio CLNN|P/S Multiple PEPG|Price-to-Revenue Ratio JUNS (Jupiter Neurosciences, Inc.)|Price-to-Revenue Ratio Relmada Therapeutics RLMD|ANVS (annovisbio.com) - Price-to-Sales Ratio|Grace Tx - P/S Multiple|Market Capitalization-to-Revenue Ratio AIFF (Firefly Neuroscience, Inc.)|anewmeds.com (KLTO) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio NRSN|RVPH (Reviva Pharmaceuticals) - P/S Multiple|Price to Sales MetaVia, Inc. MTVA|Market Cap to Revenue NRXS (NeurAxis)|P/S Multiple heliusmedical.com (HSDT)|Price-to-Revenue Ratio Passage Bio PASG|Market Capitalization-to-Revenue Ratio NEUP|NERV - Price-to-Revenue Ratio|Price to Sales athira.com|Addex Therapeutics Ltd (ADXN) - Price-to-Revenue Ratio|ALZN (Alzamend Neuro) - Price-to-Revenue Ratio|Price-to-Revenue Ratio Cyclerion Therapeutics Inc.|Price to Sales Protagenic PTIX|Price-to-Revenue Ratio Pasithea Therapeutics (KTTA)|cortigent.com - Market Cap to Revenue Ratio|P/S Multiple ATXI (Avenue Therapeutics, Inc.)|Price-to-Revenue Multiple Brainstorm Cell Therapeutics Inc.|Cara Therapeutics, Inc - P/S Multiple|CHRO: Price-to-Revenue Ratio|eliemtx.com (ELYM) - Price-to-Revenue Ratio|Price to Sales Intra-Cellular Therapies, Inc. (ITCI)|MRNS (Marinus Pharmaceuticals, Inc.) - P/S Multiple|P/S Multiple NKGen Biotech Inc|Price-to-Revenue Ratio NeuroBo (NRBO)|SAGE (Sage Therapeutics Inc) - Market Capitalization-to-Revenue Ratio|P/S Multiple SNPX (Synaptogenix, Inc.)|TRVN: Market Cap to Revenue Ratio|VIGL: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio WENA (anewmeds.com)|Cerevel (CERE) - Price-to-Revenue Ratio
